H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics to $30 from $32 and keeps a Buy rating on the shares post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RLAY:
- Relay Therapeutics reports Q2 EPS (81c), consensus (81c)
- Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
- Relay Therapeutics initiated with an Outperform at SVB Securities
- Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023